Home Cart Sign in  
Chemical Structure| 519032-08-7 Chemical Structure| 519032-08-7

Structure of 519032-08-7

Chemical Structure| 519032-08-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of [ 519032-08-7 ]

CAS No. :519032-08-7
Formula : C17H19N3O6
M.W : 361.35
SMILES Code : O=C(C1=NC(C(C)(NC(OCC2=CC=CC=C2)=O)C)=NC(O)=C1O)OC
MDL No. :MFCD12026362
InChI Key :NIVUTAZNLHLBAN-UHFFFAOYSA-N
Pubchem ID :135446261

Safety of [ 519032-08-7 ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H332-H335
Precautionary Statements:P261-P280-P305+P351+P338

Computational Chemistry of [ 519032-08-7 ] Show Less

Physicochemical Properties

Num. heavy atoms 26
Num. arom. heavy atoms 12
Fraction Csp3 0.29
Num. rotatable bonds 8
Num. H-bond acceptors 8.0
Num. H-bond donors 3.0
Molar Refractivity 90.4
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

130.87 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

2.75
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

2.2
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

1.58
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

0.52
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

1.26
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

1.66

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

-3.28
Solubility 0.19 mg/ml ; 0.000525 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

-4.58
Solubility 0.00945 mg/ml ; 0.0000262 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Moderately soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-4.02
Solubility 0.0347 mg/ml ; 0.0000959 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Moderately soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

No
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

Yes
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

No
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

No
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

No
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

No
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-6.94 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

0.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.55

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

1.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<2.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

3.32

Application In Synthesis of [ 519032-08-7 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 519032-08-7 ]

[ 519032-08-7 ] Synthesis Path-Upstream   1~6

  • 1
  • [ 518047-98-8 ]
  • [ 762-42-5 ]
  • [ 519032-08-7 ]
YieldReaction ConditionsOperation in experiment
58%
Stage #1: at 20℃; for 2 h;
Stage #2: With xylene In methanol at 90 - 120℃; for 16 h; Inert atmosphere
Benzyl 2-amino-2-(hydroxyimino)-1,1-dimethylethylcarbamate (2.0 g, 8.0 mmol) was dissolved in 30 mL MeOH, dimethyl acetylenedicarboxylate (DMAD, 1.1 mL, 9.0 mmol) was added slowly. The mixture was stirred for 2 h at room temperature, and then concentrated under reduced pressure to give a white oil. The mixture of the oil and 80 mL xylene was stirred at 90 °C for 2 h and 120 °C for 2 h, then refluxed for 12 h under nitrogen, concentrated to yield the crude product. The crude product was recrystallized with 2 mL MeOH and 10 mL tert-butyl methyl ether to afford 5 as a yellow solid (1.7 g, 58 percent): 1H-NMR (DMSO-d6) δ: 7.35 (m, 5H), 5.00 (s, 2H), 3.83 (s, 3H), 1.48 (s, 6H); ESI-MS m/z 360 (M), 384 (M+Na) +.
References: [1] Bioorganic and Medicinal Chemistry Letters, 2012, vol. 22, # 23, p. 7114 - 7118.
  • 2
  • [ 100134-82-5 ]
  • [ 519032-08-7 ]
References: [1] Journal of Medicinal Chemistry, 2007, vol. 50, # 9, p. 2225 - 2239.
[2] Bioorganic and Medicinal Chemistry Letters, 2012, vol. 22, # 23, p. 7114 - 7118.
  • 3
  • [ 501-53-1 ]
  • [ 519032-08-7 ]
References: [1] Journal of Medicinal Chemistry, 2007, vol. 50, # 9, p. 2225 - 2239.
  • 4
  • [ 1064707-10-3 ]
  • [ 519032-08-7 ]
References: [1] Journal of Medicinal Chemistry, 2008, vol. 51, # 18, p. 5843 - 5855.
  • 5
  • [ 1064707-10-3 ]
  • [ 519032-08-7 ]
References: [1] Journal of Medicinal Chemistry, 2007, vol. 50, # 9, p. 2225 - 2239.
  • 6
  • [ 518047-98-8 ]
  • [ 519032-08-7 ]
References: [1] Journal of Medicinal Chemistry, 2007, vol. 50, # 9, p. 2225 - 2239.
 

Historical Records

Technical Information

Categories

Related Functional Groups of
[ 519032-08-7 ]

Aryls

Chemical Structure| 62222-38-2

A245169 [62222-38-2]

5,6-Dihydroxy-2-phenylpyrimidine-4-carboxylic acid

Similarity: 0.72

Chemical Structure| 888504-27-6

A102401 [888504-27-6]

Methyl 2-(2-(((benzyloxy)carbonyl)amino)propan-2-yl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxylate

Similarity: 0.57

Chemical Structure| 519028-33-2

A133159 [519028-33-2]

Benzyl (2-(4-((4-fluorobenzyl)carbamoyl)-5-hydroxy-6-oxo-1,6-dihydropyrimidin-2-yl)propan-2-yl)carbamate

Similarity: 0.54

Chemical Structure| 1377049-84-7

A470907 [1377049-84-7]

Methyl ((2S)-1-((2S,5S)-2-(9-(2-((2S,4S)-1-((2R)-2-((methoxycarbonyl)amino)-2-phenylacetyl)-4-(methoxymethyl)pyrrolidin-2-yl)-1H-imidazol-5-yl)-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol-2-yl)-5-methylpyrrolidin-1-yl)-3-methyl-1-oxobutan-2-yl)carbamate

Similarity: 0.54

Chemical Structure| 518048-02-7

A154209 [518048-02-7]

Benzyl [1-[4-[[(4-fluorobenzyl)amino]carbonyl]-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidin-2-yl]-1-methylethyl]carbamate

Similarity: 0.53

Alcohols

Chemical Structure| 62222-38-2

A245169 [62222-38-2]

5,6-Dihydroxy-2-phenylpyrimidine-4-carboxylic acid

Similarity: 0.72

Chemical Structure| 878158-18-0

A144548 [878158-18-0]

Methyl 5,6-dihydroxy-2-methylpyrimidine-4-carboxylate

Similarity: 0.68

Chemical Structure| 858956-25-9

A271643 [858956-25-9]

2-Cyclopropyl-6-hydroxypyrimidine-4-carboxylic acid

Similarity: 0.58

Chemical Structure| 888504-27-6

A102401 [888504-27-6]

Methyl 2-(2-(((benzyloxy)carbonyl)amino)propan-2-yl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxylate

Similarity: 0.57

Chemical Structure| 1256791-78-2

A929244 [1256791-78-2]

Methyl 5-hydroxy-6-methoxypicolinate

Similarity: 0.57

Amides

Chemical Structure| 888504-27-6

A102401 [888504-27-6]

Methyl 2-(2-(((benzyloxy)carbonyl)amino)propan-2-yl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxylate

Similarity: 0.57

Chemical Structure| 519028-33-2

A133159 [519028-33-2]

Benzyl (2-(4-((4-fluorobenzyl)carbamoyl)-5-hydroxy-6-oxo-1,6-dihydropyrimidin-2-yl)propan-2-yl)carbamate

Similarity: 0.54

Chemical Structure| 1377049-84-7

A470907 [1377049-84-7]

Methyl ((2S)-1-((2S,5S)-2-(9-(2-((2S,4S)-1-((2R)-2-((methoxycarbonyl)amino)-2-phenylacetyl)-4-(methoxymethyl)pyrrolidin-2-yl)-1H-imidazol-5-yl)-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol-2-yl)-5-methylpyrrolidin-1-yl)-3-methyl-1-oxobutan-2-yl)carbamate

Similarity: 0.54

Chemical Structure| 1206524-85-7

A127506 [1206524-85-7]

8H-7,10-methanocyclopropa[18,19][1,10,3,6]dioxadiazacyclononadecino[11,12-b]quinoxaline-8-carboxylic acid, 5-(1,1-dimethylethyl)-1,1a,3,4,5,6,9,10,18,19,20,21,22,22a-tetradecahydro-14-methoxy-3,6-dioxo-, (1ar,5s,8s,10r,22ar)-

Similarity: 0.53

Chemical Structure| 518048-02-7

A154209 [518048-02-7]

Benzyl [1-[4-[[(4-fluorobenzyl)amino]carbonyl]-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidin-2-yl]-1-methylethyl]carbamate

Similarity: 0.53

Esters

Chemical Structure| 878158-18-0

A144548 [878158-18-0]

Methyl 5,6-dihydroxy-2-methylpyrimidine-4-carboxylate

Similarity: 0.68

Chemical Structure| 888504-27-6

A102401 [888504-27-6]

Methyl 2-(2-(((benzyloxy)carbonyl)amino)propan-2-yl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxylate

Similarity: 0.57

Chemical Structure| 1256791-78-2

A929244 [1256791-78-2]

Methyl 5-hydroxy-6-methoxypicolinate

Similarity: 0.57

Chemical Structure| 1260883-63-3

A248248 [1260883-63-3]

Methyl 5,6-dihydroxypicolinate

Similarity: 0.55

Chemical Structure| 5965-59-3

A170724 [5965-59-3]

Methyl 4-hydroxyquinoline-2-carboxylate

Similarity: 0.54

Amines

Chemical Structure| 888504-27-6

A102401 [888504-27-6]

Methyl 2-(2-(((benzyloxy)carbonyl)amino)propan-2-yl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxylate

Similarity: 0.57

Chemical Structure| 519028-33-2

A133159 [519028-33-2]

Benzyl (2-(4-((4-fluorobenzyl)carbamoyl)-5-hydroxy-6-oxo-1,6-dihydropyrimidin-2-yl)propan-2-yl)carbamate

Similarity: 0.54

Chemical Structure| 1377049-84-7

A470907 [1377049-84-7]

Methyl ((2S)-1-((2S,5S)-2-(9-(2-((2S,4S)-1-((2R)-2-((methoxycarbonyl)amino)-2-phenylacetyl)-4-(methoxymethyl)pyrrolidin-2-yl)-1H-imidazol-5-yl)-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol-2-yl)-5-methylpyrrolidin-1-yl)-3-methyl-1-oxobutan-2-yl)carbamate

Similarity: 0.54

Chemical Structure| 518048-02-7

A154209 [518048-02-7]

Benzyl [1-[4-[[(4-fluorobenzyl)amino]carbonyl]-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidin-2-yl]-1-methylethyl]carbamate

Similarity: 0.53

Chemical Structure| 894803-87-3

A268824 [894803-87-3]

Methyl 4-amino-6-ethoxypicolinate

Similarity: 0.53

Related Parent Nucleus of
[ 519032-08-7 ]

Pyrimidines

Chemical Structure| 62222-38-2

A245169 [62222-38-2]

5,6-Dihydroxy-2-phenylpyrimidine-4-carboxylic acid

Similarity: 0.72

Chemical Structure| 878158-18-0

A144548 [878158-18-0]

Methyl 5,6-dihydroxy-2-methylpyrimidine-4-carboxylate

Similarity: 0.68

Chemical Structure| 858956-25-9

A271643 [858956-25-9]

2-Cyclopropyl-6-hydroxypyrimidine-4-carboxylic acid

Similarity: 0.58

Chemical Structure| 888504-27-6

A102401 [888504-27-6]

Methyl 2-(2-(((benzyloxy)carbonyl)amino)propan-2-yl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxylate

Similarity: 0.57

Chemical Structure| 519028-33-2

A133159 [519028-33-2]

Benzyl (2-(4-((4-fluorobenzyl)carbamoyl)-5-hydroxy-6-oxo-1,6-dihydropyrimidin-2-yl)propan-2-yl)carbamate

Similarity: 0.54